| Drug Name |
Fluticasone furoate |
| Drug ID |
BADD_D00946 |
| Description |
Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965]. |
| Indications and Usage |
Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo Ellipta should not be used for the relief of acute symptoms of asthma or COPD. |
| Marketing Status |
Prescription; OTC |
| ATC Code |
D07AC17; R01AD08; R01AD12; R03BA05; R03BA09 |
| DrugBank ID |
DB08906
|
| KEGG ID |
D06315
|
| MeSH ID |
C523187
|
| PubChem ID |
9854489
|
| TTD Drug ID |
D0Y7JU
|
| NDC Product Code |
63379-083; 59057-009; 52482-008; 47848-057; 0173-0876; 64918-1915; 55018-302; 0135-0616; 64918-1916; 0135-0615; 15308-2021; 58175-0553; 0173-0874; 59057-010; 63379-084; 49076-6451; 64918-1117; 22552-0042; 0173-0888; 63592-3370; 49076-6452; 64918-1910 |
| Synonyms |
fluticasone furoate |
